KR101555293B1 - 저점도이면서 고도 응집된 유리체내 주사용 트리암시놀론 아세토니드 현탁액 - Google Patents

저점도이면서 고도 응집된 유리체내 주사용 트리암시놀론 아세토니드 현탁액 Download PDF

Info

Publication number
KR101555293B1
KR101555293B1 KR1020107022609A KR20107022609A KR101555293B1 KR 101555293 B1 KR101555293 B1 KR 101555293B1 KR 1020107022609 A KR1020107022609 A KR 1020107022609A KR 20107022609 A KR20107022609 A KR 20107022609A KR 101555293 B1 KR101555293 B1 KR 101555293B1
Authority
KR
South Korea
Prior art keywords
suspension composition
settling
suspension
chloride
triamcinolone acetonide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020107022609A
Other languages
English (en)
Korean (ko)
Other versions
KR20100127267A (ko
Inventor
바그와티 피. 카브라
루마 사카르
Original Assignee
알콘 리서치, 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알콘 리서치, 리미티드 filed Critical 알콘 리서치, 리미티드
Publication of KR20100127267A publication Critical patent/KR20100127267A/ko
Application granted granted Critical
Publication of KR101555293B1 publication Critical patent/KR101555293B1/ko
Assigned to 알콘 리서치, 엘엘씨 reassignment 알콘 리서치, 엘엘씨 권리의 전부이전등록 Assignors: 알콘 리서치, 리미티드
Assigned to 알콘 인코포레이티드 reassignment 알콘 인코포레이티드 권리의 전부이전등록 Assignors: 알콘 리서치, 엘엘씨
Assigned to 노파르티스 아게 reassignment 노파르티스 아게 권리의 전부이전등록 Assignors: 알콘 인코포레이티드
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
KR1020107022609A 2008-03-11 2009-03-10 저점도이면서 고도 응집된 유리체내 주사용 트리암시놀론 아세토니드 현탁액 Active KR101555293B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3545908P 2008-03-11 2008-03-11
US61/035,459 2008-03-11

Publications (2)

Publication Number Publication Date
KR20100127267A KR20100127267A (ko) 2010-12-03
KR101555293B1 true KR101555293B1 (ko) 2015-10-06

Family

ID=40548758

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020107022609A Active KR101555293B1 (ko) 2008-03-11 2009-03-10 저점도이면서 고도 응집된 유리체내 주사용 트리암시놀론 아세토니드 현탁액

Country Status (21)

Country Link
US (3) US8128960B2 (https=)
EP (1) EP2262506B1 (https=)
JP (1) JP5581227B2 (https=)
KR (1) KR101555293B1 (https=)
CN (1) CN101959519B (https=)
AR (1) AR070824A1 (https=)
AU (1) AU2009223649B2 (https=)
BR (1) BRPI0909630B8 (https=)
CA (1) CA2717605C (https=)
CL (1) CL2009000573A1 (https=)
DK (1) DK2262506T3 (https=)
ES (1) ES2471122T3 (https=)
MX (1) MX2010009974A (https=)
PL (1) PL2262506T3 (https=)
PT (1) PT2262506E (https=)
RU (1) RU2481842C2 (https=)
SI (1) SI2262506T1 (https=)
TW (1) TWI468165B (https=)
UY (1) UY31699A1 (https=)
WO (1) WO2009114521A1 (https=)
ZA (1) ZA201005839B (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070202186A1 (en) 2006-02-22 2007-08-30 Iscience Interventional Corporation Apparatus and formulations for suprachoroidal drug delivery
JP5581227B2 (ja) * 2008-03-11 2014-08-27 アルコン リサーチ， リミテッド 硝子体内注射のための低粘度、高凝集トリアムシノロンアセトニド懸濁剤
AU2009330517A1 (en) * 2008-12-22 2010-07-01 Alcon Research, Ltd. Compositions of topical ocular solutions to deliver effective concentrations of active agent to the posterior segment of the eye
JP5996544B2 (ja) 2010-10-15 2016-09-21 クリアサイド・バイオメディカル・インコーポレーテッドＣｌｅａｒｓｉｄｅ Ｂｉｏｍｅｄｉｃａｌ Ｉｎｃｏｒｐｏｒａｔｅｄ 眼球アクセス用装置
CN102008488B (zh) * 2010-11-24 2012-10-10 广州固志医药科技有限公司 一种曲安奈德眼用制剂及其制备方法
AR090775A1 (es) * 2012-04-23 2014-12-03 Otsuka Pharma Co Ltd Preparado inyectable
MX373894B (es) * 2012-11-08 2020-07-09 Clearside Biomedical Inc Métodos y dispositivos para el tratamiento de trastornos oculares en sujetos humanos.
BR112015027762A2 (pt) 2013-05-03 2017-08-29 Clearside Biomedical Inc Aparelho e métodos para injeção ocular
WO2014197317A1 (en) 2013-06-03 2014-12-11 Clearside Biomedical, Inc. Apparatus and methods for drug delivery using multiple reservoirs
EP3157598A4 (en) 2014-06-20 2018-05-16 Clearside Biomedical, Inc. Variable diameter cannula and methods for controlling insertion depth for medicament delivery
US9694145B1 (en) 2016-03-29 2017-07-04 Joseph Onorato Auto-injector systems and method for delivering cyst medication on demand
EP3452165A1 (en) 2016-05-02 2019-03-13 Clearside Biomedical, Inc. Systems and methods for ocular drug delivery
IL305537B2 (en) 2016-08-12 2025-02-01 Clearside Biomedical Inc Devices and methods for adjusting the insertion depth of a needle for administering a drug
US12090294B2 (en) 2017-05-02 2024-09-17 Georgia Tech Research Corporation Targeted drug delivery methods using a microneedle
AU2019207515B2 (en) * 2018-01-10 2024-11-14 Eye Co Pty Ltd Medical device and pharmaceutical composition for treatment of an eye disease or condition
USD893715S1 (en) 2018-11-06 2020-08-18 Joseph Onorato Measurement guide for a cyst, lesion or skin disorder
CA3136814A1 (en) * 2019-04-16 2020-10-22 Clearside Biomedical, Inc. Injectable triamcinolone formulations
US10814001B1 (en) 2019-05-06 2020-10-27 Rvl Pharmaceuticals, Inc. Oxymetazoline compositions
CN114010593A (zh) * 2021-11-23 2022-02-08 莱默(北京)药业科技有限公司 一种曲安奈德混悬注射液及制备方法
CN115969784B (zh) * 2022-12-26 2025-10-21 昆明积大制药股份有限公司 曲安奈德注射液的制备方法
WO2025114562A1 (en) * 2023-11-30 2025-06-05 Institut National de la Santé et de la Recherche Médicale Intravitreal spironolactone suspension

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005032510A1 (en) 2003-09-23 2005-04-14 Alcon, Inc. Triamcinolone acetonide and anecortave acetate formulations for injection
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3962430A (en) * 1974-08-07 1976-06-08 Merck & Co., Inc. Sterilization of solid non-electrolyte medicinal agents employing sodium chloride
US4370325A (en) * 1979-03-30 1983-01-25 Dermik Laboratories Pharmaceutical compositions and method of treatment
US4432964A (en) * 1981-08-24 1984-02-21 Alza Corporation Topical composition containing steroid in two forms released independently from polymeric carrier
US5164190A (en) * 1990-12-11 1992-11-17 Theratech, Inc. Subsaturated transdermal drug delivery device exhibiting enhanced drug flux
US5770589A (en) 1993-07-27 1998-06-23 The University Of Sydney Treatment of macular degeneration
WO1996020712A1 (en) 1994-12-30 1996-07-11 American Home Products Corporation Clear non-alcoholic hydrocortisone solutions
CA2336703A1 (en) 1998-07-10 2000-01-20 The University Of Sydney Prophylactic treatments of neovascularisation in macular degeneration
AR026073A1 (es) 1999-10-20 2002-12-26 Nycomed Gmbh Composicion farmaceutica acuosa que contiene ciclesonida
AUPQ496500A0 (en) 2000-01-06 2000-02-03 University Of Sydney, The Kit
US6395294B1 (en) 2000-01-13 2002-05-28 Gholam A. Peyman Method of visualization of the vitreous during vitrectomy
US6656505B2 (en) * 2000-07-21 2003-12-02 Alpharma Uspd Inc. Method for forming an aqueous flocculated suspension
WO2002015878A1 (fr) * 2000-08-25 2002-02-28 Senju Pharmaceutical Co., Ltd. Preparations en suspension aqueuse
HRP20040102A2 (en) * 2001-07-09 2004-10-31 Combinatorx Combinations for the treatment of inflammatory disorders
US20030129242A1 (en) 2002-01-04 2003-07-10 Bosch H. William Sterile filtered nanoparticulate formulations of budesonide and beclomethasone having tyloxapol as a surface stabilizer
WO2004073607A2 (en) * 2003-02-20 2004-09-02 Alcon, Inc. Use of steroids to treat ocular disorders
US20040186084A1 (en) 2003-03-21 2004-09-23 Akorn, Inc. Triamcinolone formulations and methods for their preparation and use
US20050101582A1 (en) 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
US20060141049A1 (en) 2003-11-12 2006-06-29 Allergan, Inc. Triamcinolone compositions for intravitreal administration to treat ocular conditions
US20070224278A1 (en) 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
US20050169992A1 (en) * 2003-12-23 2005-08-04 Frank Jao Methods and dosage forms for increasing solubility of drug compositions for controlled delivery
DE602005011928D1 (de) 2004-01-20 2009-02-05 Allergan Inc Zusammensetzungen für die lokalisierte therapie des auges, vorzugsweise enthaltend triamcinolon-acetonid und hyaluronsäure
US20070225727A1 (en) 2004-05-31 2007-09-27 Keiichi Matsuhisa Transparent Tissue-Visualizng Preparation
US8246949B2 (en) 2004-10-27 2012-08-21 Aciont, Inc. Methods and devices for sustained in-vivo release of an active agent
AU2005306309A1 (en) 2004-11-17 2006-05-26 Government Of The U.S.A., As Represented By The Secretary, Department Of Health & Human Services Steroid formulation and methods of treatment using same
EP1867334A4 (en) 2005-02-18 2009-07-15 Santen Pharmaceutical Co Ltd METHOD FOR RELIEVING OR AVOIDING A SECONDARY EFFECT OF A STEROID COMPOUND
US7893040B2 (en) * 2005-07-22 2011-02-22 Oculis Ehf Cyclodextrin nanotechnology for ophthalmic drug delivery
ITRM20050547A1 (it) 2005-11-04 2007-05-05 Sooft Italia S R L Gel oftalmico composto da triamcinolone acetonide e da un polimero poliacrilico.
JP5581227B2 (ja) * 2008-03-11 2014-08-27 アルコン リサーチ， リミテッド 硝子体内注射のための低粘度、高凝集トリアムシノロンアセトニド懸濁剤

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005032510A1 (en) 2003-09-23 2005-04-14 Alcon, Inc. Triamcinolone acetonide and anecortave acetate formulations for injection
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments

Also Published As

Publication number Publication date
TWI468165B (zh) 2015-01-11
MX2010009974A (es) 2010-09-30
US8128960B2 (en) 2012-03-06
US20120116216A1 (en) 2012-05-10
EP2262506B1 (en) 2014-05-07
CL2009000573A1 (es) 2010-01-04
ES2471122T3 (es) 2014-06-25
TW200940071A (en) 2009-10-01
RU2481842C2 (ru) 2013-05-20
CA2717605C (en) 2012-05-15
KR20100127267A (ko) 2010-12-03
US20120115829A1 (en) 2012-05-10
SI2262506T1 (sl) 2014-07-31
CN101959519B (zh) 2013-03-20
BRPI0909630B1 (pt) 2019-03-26
JP2011513492A (ja) 2011-04-28
AR070824A1 (es) 2010-05-05
CN101959519A (zh) 2011-01-26
DK2262506T3 (da) 2014-06-10
BRPI0909630A2 (pt) 2015-09-22
EP2262506A1 (en) 2010-12-22
RU2010141542A (ru) 2012-04-20
JP5581227B2 (ja) 2014-08-27
AU2009223649A1 (en) 2009-09-17
US8211880B2 (en) 2012-07-03
HK1146464A1 (en) 2011-06-10
ZA201005839B (en) 2011-10-26
AU2009223649B2 (en) 2013-08-29
UY31699A1 (es) 2009-05-29
CA2717605A1 (en) 2009-09-17
BRPI0909630B8 (pt) 2021-05-25
WO2009114521A1 (en) 2009-09-17
US20090233890A1 (en) 2009-09-17
PL2262506T3 (pl) 2014-09-30
PT2262506E (pt) 2014-06-24

Similar Documents

Publication Publication Date Title
KR101555293B1 (ko) 저점도이면서 고도 응집된 유리체내 주사용 트리암시놀론 아세토니드 현탁액
US9089478B2 (en) Peripherally administered viscous formulations
JP5732058B2 (ja) 眼科用水性注射可能組成物およびその使用方法
Al-Tahami et al. Smart polymer based delivery systems for peptides and proteins
WO2008098212A2 (en) Extended release formulations of glucagon and other peptides and proteins
KR20150114505A (ko) 불용성 코르티코스테로이드 및 수용성 코르티코스테로이드를 포함하는 약학적 제형
JPH11514650A (ja) 治療用シスプラチン（ｃｄｄｐ）のための改良された方法及び組成物
CN1852700A (zh) 曲安奈德和醋酸阿奈可他注射用制剂
TWI674899B (zh) 醫藥配方
WO2016036588A1 (en) Pharmaceutical suspensions containing etoricoxib
CN104721130B (zh) 一种布林佐胺包合物眼用制剂及其制备方法
HK1146464B (en) Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection
JPS611621A (ja) インシュリン製剤

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20101008

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20140221

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20150207

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20150704

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20150917

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20150918

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20180903

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20180903

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20190829

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20190829

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20200914

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20220830

Start annual number: 8

End annual number: 8